Skip Navigation



JAC Advance Access published online on September 1, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki308
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/4/738    most recent
dki308v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Almond, L. M.
Right arrow Articles by Back, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almond, L. M.
Right arrow Articles by Back, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received May 27, 2005
Revised August 2, 2005
Accepted August 4, 2005

Original article

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals

Lisa M. Almond 1*, Patrick G. Hoggard 1, Damitha Edirisinghe 2, Saye H. Khoo 1, and David J. Back 1

1 Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
2 Department of G.U. Medicine, Royal Liverpool University Hospital, Liverpool, UK

* To whom correspondence should be addressed.
Lisa M. Almond, E-mail: lisaa{at}liv.ac.uk


  Abstract

Objectives: The site of action of efavirenz is inside HIV-infected cells. Measurement of intracellular (IC) concentrations of efavirenz may therefore provide further understanding of therapeutic failure, especially where virological rebound occurs despite adequate plasma levels, and a lack of detectable viral resistance. Here, we determined IC and plasma pharmacokinetics of efavirenz and their relationship with plasma protein binding and P-glycoprotein (P-gp, an active drug efflux transporter) expression.

Patients and methods: Venous blood samples from 10 HIV-infected patients receiving efavirenz (600 mg once a day plus two nucleoside reverse transcriptase inhibitors) were collected over the 24 h dosing interval. Plasma and peripheral blood mononuclear cells (PBMCs) were isolated. Plasma protein bound and unbound efavirenz were separated using ultrafiltration. IC (or cell-associated), total plasma and unbound plasma efavirenz levels were quantified using HPLC-UV. P-gp expression was measured by flow cytometry. Area under the concentration-time curves (AUC0-24) were then calculated using non-compartmental analyses and the IC accumulation expressed as a ratio of IC to plasma AUC0-24.

Results: The median (range) % unbound and IC accumulation ratio was 0.6% (0.4-1.5%) and 1.3 (0.7-3.3), respectively. There was a linear relationship between IC and total AUC0-24 (r2 = 0.59, P = 0.01) but not unbound AUC0-24 (r2 = 0.13, P = 0.75). An inverse correlation between IC AUC0-24 and % unbound was observed (r2 = 41, P = 0.05). There was no relationship between IC AUC0-24 and P-gp expression on the cell surface (r2 < 0.01, P = 0.98).

Conclusions: There was a direct relationship between % bound efavirenz in plasma and IC accumulation implying that the IC accumulation of efavirenz is related to binding to IC proteins or other cellular constituents. Studies investigating the unbound concentration of antiretrovirals inside the cell are now required.

Keywords: antiretrovirals; non-nucleoside reverse transcriptase inhibitors; NNRTIs.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
F. Maggiolo
Efavirenz: a decade of clinical experience in the treatment of HIV
J. Antimicrob. Chemother., November 1, 2009; 64(5): 910 - 928.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
O. Janneh, B. Chandler, R. Hartkoorn, W. S. Kwan, C. Jenkinson, S. Evans, D. J. Back, A. Owen, and S. H. Khoo
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes
J. Antimicrob. Chemother., November 1, 2009; 64(5): 1002 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. A. Perez-Molina, P. Domingo, E. Martinez, and S. Moreno
The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy
J. Antimicrob. Chemother., August 1, 2008; 62(2): 234 - 245.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Wyen, H. Hendra, M. Vogel, C. Hoffmann, H. Knechten, N. H. Brockmeyer, J. R. Bogner, J. Rockstroh, S. Esser, H. Jaeger, et al.
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
J. Antimicrob. Chemother., April 1, 2008; 61(4): 914 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. Tanaka, H. Hanabusa, E. Kinai, N. Hasegawa, M. Negishi, and S. Kato
Intracellular Efavirenz Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Individuals
Antimicrob. Agents Chemother., February 1, 2008; 52(2): 782 - 785.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Roucairol, S. Azoulay, M.-C. Nevers, C. Creminon, T. Lavrut, R. Garraffo, J. Grassi, A. Burger, and D. Duval
Quantitative Immunoassay To Measure Plasma and Intracellular Atazanavir Levels: Analysis of Drug Accumulation in Cultured T Cells
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 405 - 411.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Friedland, S. Khoo, C. Jack, and U. Lalloo
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
J. Antimicrob. Chemother., December 1, 2006; 58(6): 1299 - 1302.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Djabarouti, D. Breilh, I. Pellegrin, M. Lavit, F. Camou, O. Caubet, H. Fleury, M.-C. Saux, and J.-L. Pellegrin
Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study)
J. Antimicrob. Chemother., November 1, 2006; 58(5): 1090 - 1093.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. M. Hossain and M. A. Parniak
In Vitro Microbicidal Activity of the Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) UC781 against NNRTI-Resistant Human Immunodeficiency Virus Type 1
J. Virol., May 1, 2006; 80(9): 4440 - 4446.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.